Sam-A Pharm has been growing earnings at an average annual rate of 25.6%, while the Pharmaceuticals industry saw earnings growing at 11.9% annually. Revenues have been growing at an average rate of 9% per year. Sam-A Pharm's return on equity is 3.9%, and it has net margins of 12.5%.
How Sam-A Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A009300 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
70,928
8,887
25,284
6,870
31 Dec 25
77,799
12,940
26,505
6,136
30 Sep 25
76,659
13,187
27,721
5,002
30 Jun 25
82,518
15,344
27,260
6,008
31 Mar 25
90,126
19,000
28,468
5,241
31 Dec 24
95,581
22,080
28,393
5,421
30 Sep 24
101,393
22,768
31,640
5,091
30 Jun 24
102,550
24,744
29,988
5,637
31 Mar 24
102,511
23,936
29,739
6,105
31 Dec 23
97,211
21,374
29,083
6,398
30 Sep 23
95,931
20,338
28,825
6,431
30 Jun 23
95,324
20,387
27,750
5,441
31 Mar 23
87,159
15,531
31,390
1,451
31 Dec 22
81,700
11,912
26,661
3,771
30 Sep 22
75,479
11,029
24,036
2,977
30 Jun 22
66,172
7,520
22,587
3,258
31 Mar 22
63,638
7,000
16,024
7,600
31 Dec 21
54,666
3,392
20,814
3,829
30 Sep 21
50,907
178
20,969
3,776
30 Jun 21
50,870
-1,115
21,690
4,120
31 Mar 21
48,548
-1,650
23,102
2,847
31 Dec 20
53,653
124
22,780
3,681
30 Sep 20
59,775
3,392
22,977
4,161
30 Jun 20
64,025
5,986
25,136
4,133
31 Mar 20
70,346
9,128
25,824
4,843
31 Dec 19
71,560
10,197
26,105
5,386
30 Sep 19
70,715
9,807
27,220
5,728
31 Dec 18
66,947
8,801
26,278
4,889
Quality Earnings: A009300 has high quality earnings.
Growing Profit Margin: A009300's current net profit margins (12.5%) are lower than last year (21.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A009300 has become profitable over the past 5 years, growing earnings by 25.6% per year.
Accelerating Growth: A009300's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A009300 had negative earnings growth (-53.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).
Return on Equity
High ROE: A009300's Return on Equity (3.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/29 16:05
End of Day Share Price
2026/05/29 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sam-A Pharm. Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.